
IMDX Stock Forecast & Price Target
IMDX Analyst Ratings
Bulls say
Insight Molecular is supported by a compelling mix of reimbursement tailwinds, clinical validation, and expanding commercial pathways for its dd-cfDNA platform. The July 2026 MolDx LCD doubled testing frequency to four tests per year in years 2-3, GraftAssureCore is reimbursed at $2,753 per result, and 3Q26 revenue rose 115% year over year to $559K while gross margin reached 75.1%, with cash burn improving to -$7.3M. Management also has multiple catalysts in motion, including GALACTIC enrollment, ~7 U.S. centers already planning in-house testing in 2027, and a clear path to broader adoption through FDA authorization, Europe expansion, and the heart opportunity with a >$100M U.S. TAM.
Bears say
Insight Molecular is facing a fundamentally weaker outlook because the FDA has asked for substantial additional evidence on GraftAssureDx, including an independent accuracy study and biopsy slide review, pushing expected approval to around mid-2027 and launch to Q3'27. The company’s Q2'26 performance underscores execution pressure, with revenue of just $239k, a net loss of -$11.3M, Adj. EBITDA of -$7.8M, and roughly $18.7M of cash after burning about $10M in the quarter. A recent $15M equity offering at $1.75 per share also highlights ongoing dilution risk, while regulatory, reimbursement, and adoption hurdles could delay monetization even if the product is ultimately approved.
This aggregate rating is based on analysts' research of Insight Molecular Diagnostics Inc and is not a guaranteed prediction by Public.com or investment advice.
IMDX Analyst Forecast & Price Prediction
Start investing in IMDX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Insight Molecular Diagnostics Inc (IMDX) Forecast
IMDX Analyst Forecast & Price Prediction
Start investing in IMDX
Order type
Buy in
Order amount
Est. shares
0 shares